ResearcherKorea UniversityNo recent work listed

Chang Duck Kim

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2829-6814; OpenAlex author ID A5059886090. Sources: OpenAlex.

Their work

Papers: 3 (first author 0, last author 2)
Trials: 0
Grants: 0
Labs led: 1
Collaborators: 19

Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: 1 paper · 2017: 1 paper

Papers 3

A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreati… Co-author DOI 10.1097/md.0000000000005702 ↗
Prognostic value of inflammation-based markers in patients with pancreatic cancer administered gemcitabine and erlotinib. Last author DOI 10.4251/wjgo.v8.i7.555 ↗
Expression of heat shock protein 70 modulates the chemoresponsiveness of pancreatic cancer. Last author DOI 10.5009/gnl.2013.7.6.739 ↗

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Jong Jin Hyun · 2 shared papers, 2013–2016 · strength 0.09
- Paper Prognostic value of inflammation-based markers in patients with pancreatic cancer administered gemcitabine and erlotini… DOI 10.4251/wjgo.v8.i7.555 ↗
- Paper Expression of heat shock protein 70 modulates the chemoresponsiveness of pancreatic cancer. DOI 10.5009/gnl.2013.7.6.739 ↗
Yoon Tae Jeen · 2 shared papers, 2013–2016 · strength 0.09
- Paper Prognostic value of inflammation-based markers in patients with pancreatic cancer administered gemcitabine and erlotini… DOI 10.4251/wjgo.v8.i7.555 ↗
- Paper Expression of heat shock protein 70 modulates the chemoresponsiveness of pancreatic cancer. DOI 10.5009/gnl.2013.7.6.739 ↗
Hoon Jai Chun · 2 shared papers, 2013–2016 · strength 0.09
- Paper Prognostic value of inflammation-based markers in patients with pancreatic cancer administered gemcitabine and erlotini… DOI 10.4251/wjgo.v8.i7.555 ↗
- Paper Expression of heat shock protein 70 modulates the chemoresponsiveness of pancreatic cancer. DOI 10.5009/gnl.2013.7.6.739 ↗
Jae Min Lee · 1 shared paper, 2016 · strength 0.05
- Paper Prognostic value of inflammation-based markers in patients with pancreatic cancer administered gemcitabine and erlotini… DOI 10.4251/wjgo.v8.i7.555 ↗
Seung Woo Park · 1 shared paper, 2017 · strength 0.05
- Paper A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-… DOI 10.1097/md.0000000000005702 ↗
Si Young Song · 1 shared paper, 2017 · strength 0.05
- Paper A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-… DOI 10.1097/md.0000000000005702 ↗
Hee Seung Lee · 1 shared paper, 2017 · strength 0.05
- Paper A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-… DOI 10.1097/md.0000000000005702 ↗
Jong Ho Moon · 1 shared paper, 2017 · strength 0.05
- Paper A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-… DOI 10.1097/md.0000000000005702 ↗
Moon Jae Chung · 1 shared paper, 2017 · strength 0.05
- Paper A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-… DOI 10.1097/md.0000000000005702 ↗
Dong Uk Kim · 1 shared paper, 2017 · strength 0.05
- Paper A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-… DOI 10.1097/md.0000000000005702 ↗
Jeong Youp Park · 1 shared paper, 2017 · strength 0.05
- Paper A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-… DOI 10.1097/md.0000000000005702 ↗
Sang Hyub Lee · 1 shared paper, 2017 · strength 0.05
- Paper A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-… DOI 10.1097/md.0000000000005702 ↗
Kwang Bum Cho · 1 shared paper, 2017 · strength 0.05
- Paper A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-… DOI 10.1097/md.0000000000005702 ↗
Ho Gak Kim · 1 shared paper, 2017 · strength 0.05
- Paper A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-… DOI 10.1097/md.0000000000005702 ↗
Young Koog Cheon · 1 shared paper, 2017 · strength 0.05
- Paper A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-… DOI 10.1097/md.0000000000005702 ↗
Dong Ki Lee · 1 shared paper, 2017 · strength 0.05
- Paper A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-… DOI 10.1097/md.0000000000005702 ↗
Yong‐Tae Kim · 1 shared paper, 2017 · strength 0.05
- Paper A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-… DOI 10.1097/md.0000000000005702 ↗
Seungmin Bang · 1 shared paper, 2017 · strength 0.05
- Paper A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-… DOI 10.1097/md.0000000000005702 ↗
Chang Min Cho · 1 shared paper, 2017 · strength 0.05
- Paper A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-… DOI 10.1097/md.0000000000005702 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.